We are live on ! Find out more
PTGX icon

Protagonist Therapeutics
PTGX

156 hedge funds and large institutions have $1.34B invested in Protagonist Therapeutics in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 40 increasing their positions, 60 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

488% more call options, than puts

Call options by funds: $14.5M | Put options by funds: $2.47M

75% more funds holding in top 10

Funds holding in top 10: 4 → 7 (+3)

68% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 19

42% more capital invested

Capital invested by funds: $946M → $1.34B (+$399M)

8% more funds holding

Funds holding: 144 → 156 (+12)

3.11% more ownership

Funds ownership: 98.58% → 101.69% (+3.1%)

33% less repeat investments, than reductions

Existing positions increased: 40 | Existing positions reduced: 60

Holders
156
Holders Change
+12
Holders Change %
+8.33%
% of All Funds
2.27%
Holding in Top 10
7
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+75%
% of All Funds
0.1%
New
32
Increased
40
Reduced
60
Closed
19
Calls
$14.5M
Puts
$2.47M
Net Calls
+$12.1M
Net Calls Change
+$977K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$34.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$26.3M
3
Deutsche Bank
Deutsche Bank
Germany
+$14.7M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$10.4M
5
JFG
Jefferies Financial Group
New York
+$7.61M

Top Sellers

Rank Fund Capital Flow
1
CAC
Cowen and Company
New York
-$27.6M
2
State Street
State Street
Massachusetts
-$21.2M
3
B
Braidwell
Connecticut
-$18.5M
4
PA
Perceptive Advisors
New York
-$11.7M
5
HSBC Holdings
HSBC Holdings
United Kingdom
-$7.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
MP
26
Mangrove Partners
Connecticut
$10.1M – – –
JP Morgan Chase
27
JP Morgan Chase
New York
$9.43M +$3.13M +178,756 +77%
GC
28
Gratus Capital
Georgia
$9.12M +$1.83M +104,702 +36%
PA
29
Perceptive Advisors
New York
$8.79M -$11.7M -671,013 -64%
SCM
30
Superstring Capital Management
New York
$8.69M +$6.63M +379,143 New
IC
31
Ikarian Capital
Texas
$7.31M +$5.58M +319,000 New
N
32
Nuveen
North Carolina
$7M -$4.03M -230,605 -43%
KCM
33
Kennedy Capital Management
Missouri
$6.99M -$258K -14,744 -5%
UBS AM
34
UBS AM
Illinois
$6.63M +$3.81M +218,020 +307%
DTC
35
Deep Track Capital
Connecticut
$6.31M +$4.82M +275,201 New
CC
36
Checkpoint Capital
California
$6.12M +$4.67M +266,856 New
Two Sigma Advisers
37
Two Sigma Advisers
New York
$5.09M -$1.66M -94,900 -30%
Renaissance Technologies
38
Renaissance Technologies
New York
$4.91M -$215K -12,301 -5%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$4.66M +$30.3K +1,733 +0.9%
ACM
40
ADAR1 Capital Management
Texas
$4.61M +$3.51M +200,859 New
DCM
41
Driehaus Capital Management
Illinois
$4.56M +$3.48M +198,689 New
Walleye Capital
42
Walleye Capital
New York
$4.25M +$903K +51,610 +39%
SAM
43
Silvercrest Asset Management
New York
$4.14M +$595 +34 +0%
Rafferty Asset Management
44
Rafferty Asset Management
New York
$3.85M -$3.19M -182,486 -52%
Two Sigma Investments
45
Two Sigma Investments
New York
$3.64M -$3.11M -177,465 -53%
Bank of America
46
Bank of America
North Carolina
$3.52M -$1.5M -85,629 -36%
UBS Group
47
UBS Group
Switzerland
$3.46M +$1.05M +60,141 +66%
Millennium Management
48
Millennium Management
New York
$3.42M +$2.61M +149,163 New
Barclays
49
Barclays
United Kingdom
$3.42M -$488K -27,863 -16%
Marshall Wace
50
Marshall Wace
United Kingdom
$3.27M +$2.11M +120,723 +555%
1
2
3 4 5

PTGX Hedge Fund Activity: Q4 2023 in Review

156 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q4 2023, worth a combined $1.34B — up 42% from $946M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new PTGX positions and 19 closed out — a net gain of 13 holders — while 40 added to existing stakes and 60 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $34.2M. The largest seller was Cowen and Company, exiting entirely with an estimated $27.6M sold.

  • 156 institutional investors held Protagonist Therapeutics (PTGX) as of Q4 2023, up from 144 in Q3 2023.
  • Funds reported $1.34B of Protagonist Therapeutics stock for Q4 2023, up 42% quarter-over-quarter.
  • 32 funds opened new Protagonist Therapeutics positions in Q4 2023 and 19 closed out, a net change of +13 holders.
  • The largest Protagonist Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $34.2M added.
  • The largest Protagonist Therapeutics seller in Q4 2023 was Cowen and Company, an estimated $27.6M sold.

Based on aggregated 13F filings for Q4 2023.